Looking for big returns to supercharge your investment portfolio?
If you are, it could be worth checking out the two ASX 200 growth shares listed below that have been tipped to rise strongly from current levels.
Here's what analysts are saying about them:
Neuren Pharmaceuticals Ltd (ASX: NEU)
The first ASX 200 growth share that could have major upside potential is Neuren Pharmaceuticals.
It is a pharmaceuticals company that is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.
A recent note shows that Bell Potter is feeling very positive about the company's NNZ-2591 product candidate. It is being trialled in children with Angelman syndrome. The broker believes NNZ-2591 could give the company's earnings a big boost in the future. It explains:
Neuren Pharmaceuticals is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.
Bell Potter has a buy rating and $25.00 price target on its shares. This suggests that Neuren Pharmaceuticals shares could double in value over the next 12 months.
Web Travel Group Ltd (ASX: WEB)
Another ASX 200 growth share that could be a buy is Web Travel Group. It is a business to business travel company operating the WebBeds business.
Analysts at Goldman Sachs think that recent share price weakness has created a buying opportunity.
The broker believes that Web Travel Group is well-placed to grow rapidly over the remainder of the decade. In light of this, it feels that its shares are trading on undemanding multiples. It said:
WEB is the second largest Hotel Bed wholesaler globally with <10% of the global hotel wholesale market. We are Buy rated on WEB as we have confidence that WEB will be able to grow TTV in line with its FY25/30 targets of A$5bn/A$10bn respectively. In particular, we believe WEB is well placed to continue to grow in key US/APAC growth markets, though expect revenue margin to lower towards ~6.3% over time as the company expands into lower margin US/APAC markets. WEB is trading below fair value, on our estimates.
Goldman has a buy rating and $6.70 price target on its shares. This implies potential upside of 65% for investors from current levels.
